Record citatie

APA (7e ed.) Bronvermelding
Arisanty, D., Cuandra, K. N., Putra, A. E., Rita, R. S., Ilmiawati, C., & Anggraini, F. T. (2025). Exploring the potential of Arbacia lixula coelomic fluid peptides as cell cycle and angiogenesis inhibitor for triple-negative breast cancer therapy: In silico study. GarVal Editorial Ltda.
Chicago (17e ed.) Bronvermelding
Arisanty, Dessy, Kevin N. Cuandra, Andani E. Putra, Rauza S. Rita, Cimi Ilmiawati, en Fika T. Anggraini. Exploring the Potential of Arbacia Lixula Coelomic Fluid Peptides as Cell Cycle and Angiogenesis Inhibitor for Triple-negative Breast Cancer Therapy: In Silico Study. GarVal Editorial Ltda, 2025.
MLA (9e ed.) Bronvermelding
Arisanty, Dessy, et al. Exploring the Potential of Arbacia Lixula Coelomic Fluid Peptides as Cell Cycle and Angiogenesis Inhibitor for Triple-negative Breast Cancer Therapy: In Silico Study. GarVal Editorial Ltda, 2025.
Let op: Deze citaties zijn niet altijd 100% accuraat.